Disc Medicine, Inc. (IRON) vs NewAmsterdam Pharma Company N.V. (NAMS)
A side-by-side comparison of Disc Medicine, Inc. and NewAmsterdam Pharma Company N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IRON
Disc Medicine, Inc.
$64.11HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
NAMS
NewAmsterdam Pharma Company N.V.
$22.53HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Total return — IRON vs NAMS
growth of $100 · dividends reinvested · last 6yIRON -50.9% (-11.2%/yr)NAMS +114.9% (+13.6%/yr)NAMS compounded faster over this window
IRON NAMS
IRON vs NAMS: by the numbers
- •NAMS is the larger company ($2.63B vs $2.46B market cap).
- •Both run net losses; IRON's is the smaller (0.00% vs -3644.21% net margin).
Metrics side by side
Valuation
| Metric | IRON | NAMS |
|---|---|---|
| P/S ratio | N/A | 369.85 |
| P/B ratio | 3.82 | 4.17 |
Profitability
| Metric | IRON | NAMS |
|---|---|---|
| Gross margin | 0.00% | 92.15% |
| Operating margin | 0.00% | -1002.90% |
| Net margin | 0.00% | -3644.21% |
| ROE | -38.17% | -41.10% |
| ROIC | -38.21% | -38.70% |
Growth (annualized)
| Metric | IRON | NAMS |
|---|---|---|
| Total return CAGR (5Y) | 10.70% | 18.30% |
Frequently asked
- How have IRON and NAMS total returns compared?
- Over the past 5 years, IRON delivered 10.70% and NAMS delivered 18.30% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.